Base de dados : MEDLINE
Pesquisa : D12.644.456.345.600 [Categoria DeCS]
Referências encontradas : 1969 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 197 ir para página                         

  1 / 1969 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29212812
[Au] Autor:Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
[Ad] Endereço:From the Knight Cardiovascular Institute, Oregon Health & Science University, Portland (T.A.D.); Cardiology Section, Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC (E.Z.S.); University of Texas School of Public Health, Houston (J.-M.Y., B.R.D., L.M.S.); Depart
[Ti] Título:Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
[So] Source:Circ Arrhythm Electrophysiol;10(12), 2017 Dec.
[Is] ISSN:1941-3084
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although atrial fibrillation (AF) guidelines indicate that pharmacological blockade of the renin-angiotensin system may be considered for primary AF prevention in hypertensive patients, previous studies have yielded conflicting results. We sought to determine whether randomization to lisinopril reduces incident AF or atrial flutter (AFL) compared with chlorthalidone in a large clinical trial cohort with extended post-trial surveillance. METHODS AND RESULTS: We performed a secondary analysis of the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), a randomized, double-blind, active-controlled clinical trial that enrolled hypertensive individuals ≥55 years of age with at least one other cardiovascular risk factor. Participants were randomly assigned to receive amlodipine, lisinopril, or chlorthalidone. Individuals with elevated fasting low-density lipoprotein cholesterol levels were also randomized to pravastatin versus usual care. The primary outcome was the development of either AF or AFL as diagnosed by serial study ECGs or by Medicare claims data. Among 14 837 participants without prevalent AF or AFL, 2514 developed AF/AFL during a mean 7.5±3.2 years of follow-up. Compared with chlorthalidone, randomization to either lisinopril (hazard ratio, 1.04; 95% confidence interval, 0.94-1.15; =0.46) or amlodipine (hazard ratio, 0.93; 95% confidence interval, 0.84-1.03; =0.16) was not associated with a significant reduction in incident AF/AFL. CONCLUSIONS: Compared with chlorthalidone, treatment with lisinopril is not associated with a meaningful reduction in incident AF or AFL among older adults with a history of hypertension. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000542.
[Mh] Termos MeSH primário: Anlodipino/uso terapêutico
Anti-Hipertensivos/uso terapêutico
Fibrilação Atrial/prevenção & controle
Flutter Atrial/prevenção & controle
Clortalidona/uso terapêutico
Hipertensão/tratamento farmacológico
Lisinopril/uso terapêutico
Infarto do Miocárdio/prevenção & controle
Prevenção Primária/métodos
[Mh] Termos MeSH secundário: Anlodipino/efeitos adversos
Anti-Hipertensivos/efeitos adversos
Fibrilação Atrial/diagnóstico
Fibrilação Atrial/epidemiologia
Fibrilação Atrial/fisiopatologia
Flutter Atrial/diagnóstico
Flutter Atrial/epidemiologia
Flutter Atrial/fisiopatologia
Clortalidona/efeitos adversos
Método Duplo-Cego
Feminino
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hipertensão/diagnóstico
Hipertensão/epidemiologia
Hipertensão/fisiopatologia
Incidência
Lisinopril/efeitos adversos
Masculino
Meia-Idade
Infarto do Miocárdio/diagnóstico
Infarto do Miocárdio/epidemiologia
Infarto do Miocárdio/fisiopatologia
Fatores de Risco
Fatores de Tempo
Resultado do Tratamento
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 1J444QC288 (Amlodipine); E7199S1YWR (Lisinopril); Q0MQD1073Q (Chlorthalidone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  2 / 1969 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28577874
[Au] Autor:Heidari F; Vasudevan R; Mohd Ali SZ; Ismail P; Arkani M
[Ad] Endereço:Department of Biomedical Science, Genetic Research Group, Faculty of Medicine and Health Sciences, University Putra Malaysia, UPM Serdang Selangor, Malaysia. Electronic address: farzad720@gmail.com.
[Ti] Título:RAS Genetic Variants in Interaction with ACE Inhibitors Drugs Influences Essential Hypertension Control.
[So] Source:Arch Med Res;48(1):88-95, 2017 Jan.
[Is] ISSN:1873-5487
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUNDS AND AIMS: Essential Hypertension (EH) is a common disorder associated with increased cardiovascular morbidity and mortality in Malaysia. To investigate how genetic polymorphisms of the renin-angiotensin-aldosterone system (RAS) influence EH control with angiotensin-converting enzyme inhibitor drugs (ACEI). METHODS: A case-control, cross-sectional population-based nested study (n = 142) included hypertensive subjects treated with ACEI drugs, either lisinopril or enalapril (20 mg, once daily) as monotherapy for 24 weeks. In total seven possible polymorphisms of RAS genes were genotyped. The association between those polymorphisms and the changes in blood pressure were observed in the 24 week treatment. RESULTS: Statistically significant associations of I, G, T, M and G alleles of ACE (I/D, G2350A), AGT (M235T, T175M and G-6A) respectively were observed in essential hypertensive subjects. The decrease in systolic blood pressure and diastolic blood pressure after 24 weeks of treatment of the patients carrying II, GG, and TT genotypes were greater than the groups carrying DD, AA, MM, MM and GG of I/D, G2350A, M235T, T174M and G-6A genotypes respectively. In contrast, No significant difference was observed between renin gene polymorphisms (Bg/I and MboI) and hypertensives. CONCLUSIONS: Although this study shows a possible association of polymorphisms of RAS genes with the risk of non-control of HT in ACEI-treated patients and indicates the importance of all this system's components in regulating HT, it needs to be replicated in other data sources.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Enalapril/uso terapêutico
Hipertensão/tratamento farmacológico
Lisinopril/uso terapêutico
Sistema Renina-Angiotensina/genética
[Mh] Termos MeSH secundário: Adulto
Alelos
Pressão Sanguínea/efeitos dos fármacos
Estudos de Casos e Controles
Estudos Transversais
Hipertensão Essencial
Feminino
Genótipo
Seres Humanos
Hipertensão/genética
Hipertensão/fisiopatologia
Masculino
Meia-Idade
Polimorfismo de Nucleotídeo Único
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 69PN84IO1A (Enalapril); E7199S1YWR (Lisinopril)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170605
[St] Status:MEDLINE


  3 / 1969 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28577685
[Au] Autor:Guglin M; Munster P; Fink A; Krischer J
[Ad] Endereço:University of Kentucky, Lexington, KY. Electronic address: Maya.guglin@uky.edu.
[Ti] Título:Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
[So] Source:Am Heart J;188:87-92, 2017 Jun.
[Is] ISSN:1097-6744
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Trastuzumab (TZB) is an established therapy for HER2-positive breast cancer. The use of TZB is commonly associated with cardiotoxicity manifesting as asymptomatic decrease in left ventricular ejection fraction (LVEF) or overt heart failure. Several studies demonstrated favorable effects of angiotensin-converting enzyme (ACE) inhibitors and ß-blockers (BBs) in the prevention of chemotherapy-induced cardiotoxicity. We hypothesize that patients, randomized to receive an ACE inhibitor or a BB during trastuzumab therapy for breast cancer, will maintain a higher LVEF than patients randomized to placebo. METHODS AND RESULTS: We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy. The primary objectives include (1) comparison of incidence of cardiotoxicity and (2) comparison of LVEF as a continuous variable in between the arms. Cardiotoxicity was defined as an absolute decrease in LVEF from baseline of ≥10% at follow-up or an absolute decrease of ≥5% in LVEF from baseline for individuals with <50% LVEF at follow-up. The target accrual is 468 participants, representing patients both with and without anthracycline exposure. The enrollment is completed. The trial is co-sponsored by University of South Florida and National Cancer Institute. The LVEF is being evaluated by echocardiography or multigated acquisition scan. CONCLUSIONS: If we can demonstrate that the use of an ACE inhibitor or a BB can reduce the degree of TZB-induced cardiotoxicity, it is hoped that patients will receive complete and uninterrupted TZB therapy for breast cancer without compromising cardiac function.
[Mh] Termos MeSH primário: Neoplasias da Mama/tratamento farmacológico
Carbazóis/administração & dosagem
Lisinopril/administração & dosagem
Propanolaminas/administração & dosagem
Volume Sistólico/efeitos dos fármacos
Trastuzumab/efeitos adversos
Disfunção Ventricular Esquerda/prevenção & controle
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 1/administração & dosagem
Adulto
Inibidores da Enzima Conversora de Angiotensina/administração & dosagem
Antineoplásicos/efeitos adversos
Antineoplásicos/uso terapêutico
Neoplasias da Mama/complicações
Cardiotoxicidade/etiologia
Cardiotoxicidade/prevenção & controle
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Meia-Idade
Estudos Prospectivos
Trastuzumab/uso terapêutico
Resultado do Tratamento
Disfunção Ventricular Esquerda/induzido quimicamente
Disfunção Ventricular Esquerda/fisiopatologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Antineoplastic Agents); 0 (Carbazoles); 0 (Propanolamines); 0K47UL67F2 (carvedilol); E7199S1YWR (Lisinopril); P188ANX8CK (Trastuzumab)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170605
[St] Status:MEDLINE


  4 / 1969 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28559399
[Au] Autor:Dhruva SS; Huang C; Spatz ES; Coppi AC; Warner F; Li SX; Lin H; Xu X; Furberg CD; Davis BR; Pressel SL; Coifman RR; Krumholz HM
[Ad] Endereço:From the Robert Wood Johnson Foundation Clinical Scholars Program (S.S.D., H.M.K.), Section of Cardiovascular Medicine (E.S.S., A.C.C., F.W., H.M.K.), Department of Internal Medicine, and Department of Obstetrics, Gynecology and Reproductive Sciences (X.X.), Yale School of Medicine, New Haven, CT; D
[Ti] Título:Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
[So] Source:Hypertension;70(1):94-102, 2017 Jul.
[Is] ISSN:1524-4563
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Randomized trials of hypertension have seldom examined heterogeneity in response to treatments over time and the implications for cardiovascular outcomes. Understanding this heterogeneity, however, is a necessary step toward personalizing antihypertensive therapy. We applied trajectory-based modeling to data on 39 763 study participants of the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) to identify distinct patterns of systolic blood pressure (SBP) response to randomized medications during the first 6 months of the trial. Two trajectory patterns were identified: immediate responders (85.5%), on average, had a decreasing SBP, whereas nonimmediate responders (14.5%), on average, had an initially increasing SBP followed by a decrease. Compared with those randomized to chlorthalidone, participants randomized to amlodipine (odds ratio, 1.20; 95% confidence interval [CI], 1.10-1.31), lisinopril (odds ratio, 1.88; 95% CI, 1.73-2.03), and doxazosin (odds ratio, 1.65; 95% CI, 1.52-1.78) had higher adjusted odds ratios associated with being a nonimmediate responder (versus immediate responder). After multivariable adjustment, nonimmediate responders had a higher hazard ratio of stroke (hazard ratio, 1.49; 95% CI, 1.21-1.84), combined cardiovascular disease (hazard ratio, 1.21; 95% CI, 1.11-1.31), and heart failure (hazard ratio, 1.48; 95% CI, 1.24-1.78) during follow-up between 6 months and 2 years. The SBP response trajectories provided superior discrimination for predicting downstream adverse cardiovascular events than classification based on difference in SBP between the first 2 measurements, SBP at 6 months, and average SBP during the first 6 months. Our findings demonstrate heterogeneity in response to antihypertensive therapies and show that chlorthalidone is associated with more favorable initial response than the other medications.
[Mh] Termos MeSH primário: Anlodipino
Doenças Cardiovasculares/prevenção & controle
Clortalidona
Doxazossina
Hiperlipidemias
Hipertensão
Lisinopril
[Mh] Termos MeSH secundário: Idoso
Anlodipino/administração & dosagem
Anlodipino/efeitos adversos
Análise de Variância
Anti-Hipertensivos/administração & dosagem
Anti-Hipertensivos/efeitos adversos
Pressão Sanguínea/efeitos dos fármacos
Doenças Cardiovasculares/etiologia
Clortalidona/administração & dosagem
Clortalidona/efeitos adversos
Doxazossina/administração & dosagem
Doxazossina/efeitos adversos
Monitoramento de Medicamentos/métodos
Feminino
Seres Humanos
Hiperlipidemias/complicações
Hiperlipidemias/diagnóstico
Hiperlipidemias/tratamento farmacológico
Hipertensão/complicações
Hipertensão/diagnóstico
Hipertensão/tratamento farmacológico
Hipolipemiantes/uso terapêutico
Lisinopril/administração & dosagem
Lisinopril/efeitos adversos
Masculino
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Hypolipidemic Agents); 1J444QC288 (Amlodipine); E7199S1YWR (Lisinopril); NW1291F1W8 (Doxazosin); Q0MQD1073Q (Chlorthalidone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170601
[St] Status:MEDLINE
[do] DOI:10.1161/HYPERTENSIONAHA.117.09221


  5 / 1969 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28445490
[Au] Autor:Ali BH; Karaca T; Al Suleimani Y; Al Za'abi M; Al Kalbani J; Ashique M; Nemmar A
[Ad] Endereço:Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Al Khod, Oman.
[Ti] Título:The effect of swimming exercise on adenine-induced kidney disease in rats, and the influence of curcumin or lisinopril thereon.
[So] Source:PLoS One;12(4):e0176316, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Patients with chronic kidney disease (CKD) have been reported to benefit from different types of exercises. It has also been shown that the ACE inhibitor lisinopril, and the natural product curcumin are also beneficial in different models of CKD in rats. We assessed the influence of moderate swimming exercise (SE) on rats with adenine-induced CKD, and tested the possible effects of lisinopril and/or curcumin thereon using several physiological, biochemical, histopathological and immunohistochemical parameters. Rats (either sedentary or subjected to SE) were randomly divided into several groups, and given for five weeks either normal food or food mixed with adenine (0.25% w/w) to induce CKD. Some of these groups were also concomitantly treated orally with curcumin (75 mg/kg), or lisinopril (10 mg/kg) and were subjected to moderate SE (45 min/day three days each week). Rats fed adenine showed the typical biochemical, histopathological signs of CKD such as elevations in blood pressure, urinary albumin / creatinine ratio, and plasma urea, creatinine, indoxyl sulfate and phosphorus. SE, curcumin or lisinopril, given singly, significantly ameliorated all the adenine-induced actions. Administering curcumin or lisinopril with SE improved the histopathology of the kidneys, a salutary effect not seen with SE alone. Combining SE to the nephroprotective agents' curcumin or lisinopril might offer additional nephroprotection.
[Mh] Termos MeSH primário: Curcumina
Rim/efeitos dos fármacos
Lisinopril
Substâncias Protetoras
Insuficiência Renal Crônica/tratamento farmacológico
Natação
[Mh] Termos MeSH secundário: Adenina/toxicidade
Animais
Antioxidantes/metabolismo
Pressão Sanguínea/efeitos dos fármacos
Creatinina/sangue
Creatinina/urina
Curcumina/farmacologia
Curcumina/uso terapêutico
Modelos Animais de Doenças
Feminino
Imuno-Histoquímica
Indicã/sangue
Rim/metabolismo
Rim/patologia
Lisinopril/farmacologia
Lisinopril/uso terapêutico
Condicionamento Físico Animal
Substâncias Protetoras/farmacologia
Substâncias Protetoras/uso terapêutico
Ratos
Ratos Sprague-Dawley
Insuficiência Renal Crônica/induzido quimicamente
Insuficiência Renal Crônica/patologia
Albumina Sérica/análise
Ureia/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Protective Agents); 0 (Serum Albumin); 8W8T17847W (Urea); AYI8EX34EU (Creatinine); E7199S1YWR (Lisinopril); IT942ZTH98 (Curcumin); JAC85A2161 (Adenine); N187WK1Y1J (Indican)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0176316


  6 / 1969 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28364692
[Au] Autor:Zakrocka I; Kocki T; Turski WA
[Ad] Endereço:Department of Experimental and Clinical Pharmacology, Medical University of Lublin, Lublin, Poland. Electronic address: izabela.zakrocka@umlub.pl.
[Ti] Título:The effect of three angiotensin-converting enzyme inhibitors on kynurenic acid production in rat kidney in vitro.
[So] Source:Pharmacol Rep;69(3):536-541, 2017 Jun.
[Is] ISSN:1734-1140
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The renin-angiotensin system (RAS) is commonly known to regulate blood pressure, water and electrolyte homeostasis, however it also exerts paracrine and autocrine actions on the kidney. Angiotensin-converting enzyme inhibitors (ACE-Is), alongside their hypotensive properties, have been shown to decrease kidney function decline in animal models of nephropathy. Glutamate (GLU) is the main stimulatory neurotransmitter in the central nervous system, however its importance in the periphery should also be considered. Activation of renal GLU receptors has been linked to normal kidney function and also renal injury. The wide spectrum GLU receptor antagonist kynurenic acid (KYNA) possesses neuroprotective and central hypotensive effects, however its actions outside the brain are less well recognized. KYNA is a tryptophan metabolite synthesized from kynurenine by kynurenine aminotransferases (KATs). The purpose of this study was to examine the influence of three ACE-Is: lisinopril, perindopril and ramipril on KYNA production and KATs activity in rat kidney in vitro. METHODS: The effect of ACE-Is on KYNA production and KATs activity was examined in rat kidney homogenates. KYNA was detected by high-performance liquid chromatography (HPLC) and quantified fluorometrically. RESULTS: All examined ACE-Is: lisinopril, perindopril and ramipril decreased KYNA production in rat kidney in vitro. KAT I activity was decreased by lisinopril and ramipril whereas the activity of KAT II was lowered by ramipril. CONCLUSION: Our study shows that ACE-Is can decrease KYNA production in rat kidney in vitro. Further studies are required to determine the clinical importance of the inhibitory action of ACE-Is on KYNA synthesis in the kidney.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/farmacologia
Rim/efeitos dos fármacos
Ácido Cinurênico/metabolismo
Sistema Renina-Angiotensina/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Cromatografia Líquida de Alta Pressão
Rim/metabolismo
Lisinopril/farmacologia
Masculino
Perindopril/farmacologia
Ramipril/farmacologia
Ratos
Ratos Wistar
Transaminases/metabolismo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); E7199S1YWR (Lisinopril); EC 2.6.1.- (Transaminases); EC 2.6.1.7 (kynurenine-oxoglutarate transaminase); H030S2S85J (Kynurenic Acid); L35JN3I7SJ (Ramipril); Y5GMK36KGY (Perindopril)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170402
[St] Status:MEDLINE


  7 / 1969 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28253804
[Au] Autor:Muheim L
[Ad] Endereço:1 Institut für Hausarztmedizin, Horten-Zentrum für praxisorientierte Forschung und Wissenstransfer, Universitätsspital Zürich.
[Ti] Título:Thiaziddiuretika verringern das Risiko für Hüft- und Beckenfrakturen im Vergleich zu anderen Antihypertensiva..
[So] Source:Praxis (Bern 1994);106(5):271-272, 2017.
[Is] ISSN:1661-8157
[Cp] País de publicação:Switzerland
[La] Idioma:ger
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Fraturas Ósseas/prevenção & controle
Fraturas do Quadril/prevenção & controle
Hipertensão/tratamento farmacológico
Ossos Pélvicos/lesões
Inibidores de Simportadores de Cloreto de Sódio/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Anlodipino/uso terapêutico
Doenças Cardiovasculares/prevenção & controle
Clortalidona/uso terapêutico
Método Duplo-Cego
Substituição de Medicamentos
Feminino
Seguimentos
Seres Humanos
Lisinopril/uso terapêutico
Masculino
Meia-Idade
Risco
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Sodium Chloride Symporter Inhibitors); 1J444QC288 (Amlodipine); E7199S1YWR (Lisinopril); Q0MQD1073Q (Chlorthalidone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE
[do] DOI:10.1024/1661-8157/a002620


  8 / 1969 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28189816
[Au] Autor:Musharraf SG; Bhatti MS; Choudhary MI; Rahman AU
[Ad] Endereço:H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan; Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 7
[Ti] Título:Screening of inhibitors of angiotensin-converting enzyme (ACE) employing high performance liquid chromatography-electrospray ionization triple quadrupole mass spectrometry (HPLC-ESI-QqQ-MS).
[So] Source:Eur J Pharm Sci;101:182-188, 2017 Apr 01.
[Is] ISSN:1879-0720
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Angiotensin-converting enzyme (ACE) plays a key role in regulating blood pressure in the body by converting the angiotensin I (AI) into angiotensin II (AII). Angiotensin II is a potent vaso-active peptide that causes arterioles to constrict, resulting in increased blood pressure. A rapid and sensitive method for the identification of inhibitors of ACE was developed, and optimized employing HPLC-ESI-QqQ-MS. In this assay, angiotensin I substrate was converted into the product angiotensin II with the catalytic action of ACE. A calibration curve for depleting concentration of angiotensin I was developed and linearity of R =0.999 with a remarkably low concentration of substrate range 20-200nM. The limit of detection and quantification of angiotensin I was found to be 1.93 and 5.84nM, respectively. The enzymatic reaction was optimized for incubation time, concentration, and volume of enzyme and substrate. All reactions were performed at 37°C at pH7.5 with standard incubation time of 20min. Two standard inhibitors, Captopril and Lisinopril, were checked through the newly developed method for their inhibitory potential, and their IC values were found to be 3.969 and 0.852µM, respectively. Reproducibility and precision analysis of different experiments showed <9.9% RSD. The developed method can be used for the identification of new ACE inhibitors.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/química
Peptidil Dipeptidase A/metabolismo
[Mh] Termos MeSH secundário: Angiotensina I/metabolismo
Angiotensina II/metabolismo
Inibidores da Enzima Conversora de Angiotensina/farmacologia
Calibragem
Cromatografia Líquida de Alta Pressão/métodos
Lisinopril/química
Lisinopril/farmacologia
Peptídeos/metabolismo
Reprodutibilidade dos Testes
Espectrometria de Massas por Ionização por Electrospray/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Peptides); 11128-99-7 (Angiotensin II); 9041-90-1 (Angiotensin I); E7199S1YWR (Lisinopril); EC 3.4.15.1 (Peptidyl-Dipeptidase A)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170213
[St] Status:MEDLINE


  9 / 1969 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28111218
[Au] Autor:Sutariya B; Saraf M
[Ad] Endereço:Department of Pharmacology, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai 400068, Maharashtra, India.
[Ti] Título:Betanin, isolated from fruits of Opuntia elatior Mill attenuates renal fibrosis in diabetic rats through regulating oxidative stress and TGF-ß pathway.
[So] Source:J Ethnopharmacol;198:432-443, 2017 Feb 23.
[Is] ISSN:1872-7573
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:ETHNOPHARMACOLOGICAL RELEVANCE: The fruits of Opuntia elatior Mill are being used traditionally in different disease condition like diabetes, obesity, asthma, inflammatory disorders, and anemia. Betanin, a compound isolated from fruits of Opuntia elatior Mill has potent anti-oxidative and anti-inflammatory activity. Recent study from our lab indicated the protective effect of betanin against high glucose induced rat renal epithelial cell fibrosis and matrix accumulation, major features of diabetic nephropathy (DN). However the molecular mechanism of betanin in DN has not yet been fully elucidated. AIM OF THE STUDY: The aim of the present study was to further investigate the anti-fibrotic mechanisms of betanin against streptozotocin (STZ) induced DN. MATERIALS AND METHODS: Betanin was isolated from fruits of Opuntia elatior Mill (Cactaceae) and structure was elucidated using spectroscopy (UV, IR, 1H-NMR and mass). STZ was injected intraperitoneally with single dose of 50mg/kg for diabetes induction. In order to develop DN the animals were left in diabetes condition without any treatment during the following 4 weeks. Betanin (25, 50 and 100mg/kg/day) and lisinopril (5mg/kg/day, reference compound) were orally administered for 8 weeks after the induction of DN. Renal function, blood glucose, serum creatinine, blood urea nitrogen (BUN) and antioxidant enzyme activities in the kidney tissue were measured. Kidney tissue samples were used for glomerulosclerosis, tubulointerstitial fibrosis and morphometric studies. The expression of transforming growth factor-beta (TGF-ß), type IV collagen, alpha-smooth muscle actin (α-SMA) and E-cadherin in kidney tissue were evaluated using reverse transcription-polymerase chain reaction, and immunohistochemistry. RESULTS: Betanin was successfully isolated from fruits of Opuntia elatior Mill (Cactaceae) and purified by column chromatography. The results showed that betanin attenuated diabetic kidney injury by significantly inhibiting proteinuria, blood glucose, serum creatinine and BUN levels and restored antioxidant enzyme activities in kidney tissue. Histological studies exhibited that betanin treatment reduced the glomerular surface area, glomerulosclerosis and tubulointerstitial fibrosis. Furthermore, betanin modulated mRNA and protein expression of TGF-ß, type IV collagen, α-SMA and E-cadherin in kidney. CONCLUSIONS: The results conclude that betanin can effectively suppress renal fibrosis in DN, and may slow down the progression to end-stage renal disease by regulating TGF-ß signal pathway.
[Mh] Termos MeSH primário: Betacianinas/farmacologia
Diabetes Mellitus Experimental/tratamento farmacológico
Nefropatias Diabéticas/prevenção & controle
Opuntia/química
[Mh] Termos MeSH secundário: Animais
Betacianinas/administração & dosagem
Betacianinas/isolamento & purificação
Glicemia/efeitos dos fármacos
Nitrogênio da Ureia Sanguínea
Creatinina/sangue
Diabetes Mellitus Experimental/complicações
Relação Dose-Resposta a Droga
Feminino
Fibrose/prevenção & controle
Frutas
Lisinopril/farmacologia
Estresse Oxidativo/efeitos dos fármacos
Ratos
Ratos Sprague-Dawley
Transdução de Sinais/efeitos dos fármacos
Estreptozocina
Fator de Crescimento Transformador beta/metabolismo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Betacyanins); 0 (Blood Glucose); 0 (Transforming Growth Factor beta); 5W494URQ81 (Streptozocin); 5YJC992ZP6 (betanin); AYI8EX34EU (Creatinine); E7199S1YWR (Lisinopril)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170703
[Lr] Data última revisão:
170703
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170124
[St] Status:MEDLINE


  10 / 1969 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27984005
[Au] Autor:Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR; ALLHAT Collaborative Research Group
[Ad] Endereço:Department of Medicine, New York University School of Medicine.
[Ti] Título:Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
[So] Source:Am J Med;130(4):439-448.e9, 2017 Apr.
[Is] ISSN:1555-7162
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although hypertension guidelines define treatment-resistant hypertension as blood pressure uncontrolled by ≥3 antihypertensive medications, including a diuretic, it is unknown whether patient prognosis differs when a diuretic is included. METHODS: Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) were randomly assigned to first-step therapy with chlorthalidone, amlodipine, or lisinopril. At a Year 2 follow-up visit, those with average blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic on ≥3 antihypertensive medications, or blood pressure <140/90 mm Hg on ≥4 antihypertensive medications were identified as having apparent treatment-resistant hypertension. The prevalence of treatment-resistant hypertension and its association with ALLHAT primary (combined fatal coronary heart disease or nonfatal myocardial infarction) and secondary (all-cause mortality, stroke, heart failure, combined coronary heart disease, and combined cardiovascular disease) outcomes were identified for each treatment group. RESULTS: Of participants assigned to chlorthalidone, amlodipine, or lisinopril, 9.6%, 11.4%, and 19.7%, respectively, had treatment-resistant hypertension. During mean follow-up of 2.9 years, primary outcome incidence was similar for those assigned to chlorthalidone compared with amlodipine or lisinopril (amlodipine- vs chlorthalidone-adjusted hazard ratio [HR] 0.86; 95% confidence interval [CI], 0.53-1.39; P = .53; lisinopril- vs chlorthalidone-adjusted HR = 1.06; 95% CI, 0.70-1.60; P = .78). Secondary outcome risks were similar for most comparisons except coronary revascularization, which was higher with amlodipine than with chlorthalidone (HR 1.86; 95% CI, 1.11-3.11; P = .02). An as-treated analysis based on diuretic use produced similar results. CONCLUSIONS: In this study, which titrated medications to a goal, participants assigned to chlorthalidone were less likely to develop treatment-resistant hypertension. However, prognoses in those with treatment-resistant hypertension were similar across treatment groups.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Hipertensão/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Anlodipino/administração & dosagem
Anlodipino/uso terapêutico
Anti-Hipertensivos/administração & dosagem
Pressão Sanguínea/efeitos dos fármacos
Doenças Cardiovasculares/etiologia
Clortalidona/administração & dosagem
Clortalidona/uso terapêutico
Diuréticos/administração & dosagem
Diuréticos/uso terapêutico
Quimioterapia Combinada
Feminino
Seres Humanos
Hipertensão/complicações
Lisinopril/administração & dosagem
Lisinopril/uso terapêutico
Masculino
Falha de Tratamento
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Diuretics); 1J444QC288 (Amlodipine); E7199S1YWR (Lisinopril); Q0MQD1073Q (Chlorthalidone)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170510
[Lr] Data última revisão:
170510
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE



página 1 de 197 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde